Novartis inks marketing deal for Voltaren and Cataflam in Southeast Asia

Swiss pharma giant Novartis (NOVN: VX) has signed an agreement for the marketing, sales and distribution of its well-known pain medicine brands Voltaren (diclofenac sodium) and Cataflam(diclofenac potassium) in Malaysia, Thailand and the Philippines, with Mundipharma.

Mundipharma Southeast Asia general manager Suresh Pragasam said: "These medicines strategically complement our existing portfolio very well. We are now able to help provide relief for people suffering across the full pain spectrum - from mild to moderate to severe."

"We are delighted to have partnered with Novartis in Southeast Asia on these agreements. The deal enables us to make these world-class medicines more accessible to people in three more emerging markets, where there is not the same accessibility to medicine as there is in more mature economies. This is an example of the core Mundipharma mission in action."